fluorouracil has been researched along with Anemia in 143 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 9.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 9.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "anemia." | 7.83 | Effects and mechanisms of Bazhen decoction, Siwu decoction, and\ Sijunzi decoction on 5-fluorouracil-induced anemia in mice. ( Tian, Y; Wan, D; Wan, G; Wang, T; Xiang, Y; Yang, X; Zhu, H, 2016) |
| " We used a mouse model to examine the benefits of quercetin on CIF as measured by voluntary wheel running activity and sought to determine whether quercetin may be associated with a decrease in inflammation and/or anemia." | 7.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 7.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "Effects of fractions A and B from enzyme-digested traditional Chinese medicine colla corii asini on mice with 5-fluorouracil-induced anemia were investigated." | 7.74 | Hematopoietic effect of fractions from the enzyme-digested colla corii asini on mice with 5-fluorouracil induced anemia. ( Cui, S; Liu, J; Qin, Y; Wu, H; Yang, F; Zhang, Y, 2007) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 7.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| " As a model toxicant, we chose 5-fluorouracil (5-FU), since we previously observed that maternal administration at 20-40 mg/kg on gestational day (GD) 14 produced fetal anemia on GD 16-17, as evidenced by dose-dependent decreases in the cell counts, hematocrit, and hemoglobin content of fetal blood obtained by cardiac puncture." | 7.69 | Flow cytometric detection of abnormal fetal erythropoiesis: application to 5-fluorouracil-induced anemia. ( Elstein, KH; Rogers, JM; Shuey, DL; Zucker, RM, 1995) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 6.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 6.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| "Premenopausal breast cancer patients who developed anemia during the CMF regimen had significantly worse LRFS." | 6.73 | Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. ( Bartsch, R; Denison, U; Dubsky, P; Fridrik, M; Gnant, M; Greil, R; Hausmaninger, H; Jakesz, R; Kwasny, W; Mlineritsch, B; Pötter, R; Samonigg, H; Schippinger, W; Seifert, M; Sevelda, P; Steger, G; Stierer, M; Stöger, H; Taucher, S, 2008) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 6.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects." | 5.17 | Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 5.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "The objective of this study was to compare the effect of dose-intensified neoadjuvant chemotherapy with that of standard epirubicin plus cyclophosphamide followed by paclitaxel in combination with or without darbepoetin on survival in primary breast cancer." | 5.15 | PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa ( Beckmann, MW; Conrad, U; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Konecny, GE; Kurzeder, C; Lebeau, A; Lenhard, M; Liedtke, B; Loibl, S; Lück, HJ; Müller, V; Nekljudova, V; Salat, C; Schmidt, M; Stickeler, E; Untch, M; Urbaczyk, H; von Minckwitz, G, 2011) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients." | 5.12 | The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. ( Aglietta, M; Alabiso, I; Alabiso, O; Berruti, A; Bitossi, R; Brizzi, MP; Dogliotti, L; Forti, L; Gorzegno, G; Harris, A; Magnino, A; Miraglia, S; Saini, A; Sculli, CM; Sperti, E; Tampellini, M, 2006) |
| "The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas." | 5.11 | Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "This study investigated the efficacy and tolerability of FEC 100 (epirubicin 100 mg/m2 with 5-fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2) every 21 days as neoadjuvant chemotherapy in women with stage I-III primary operable breast cancer." | 5.11 | Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. ( Abrial, CJ; Amat, S; Chollet, PJ; Curé, HD; Feillel, VA; Ferrière, JP; Kwiatkowski, FG; Lebouëdec, G; Mouret-Reynier, MA; Penault-Llorca, FM, 2004) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "The effects of weekly subcutaneous recombinant human erythropoietin (r-hEPO) administration on anemia during chemotherapy including cisplatin and 5-fluorouracil in patients with head and neck carcinomas were examined." | 5.08 | Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. ( Itoh, K; Kawai, S; Kohno, H; Kokatsu, T; Tsukuda, M; Yuyama, S, 1998) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU." | 5.05 | Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens." | 3.91 | Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| " We used a mouse model to examine the benefits of quercetin on CIF as measured by voluntary wheel running activity and sought to determine whether quercetin may be associated with a decrease in inflammation and/or anemia." | 3.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
| "Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits." | 3.79 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 3.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "In Kit(Y567F/Y567F) mice, steady-state erythropoiesis was unperturbed while recovery from anemia due to 5-fluorouracil or phenylhydrazine was markedly impaired." | 3.75 | A KIT juxtamembrane PY567 -directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis. ( Agosti, V; Besmer, P; Karur, V; Sathyanarayana, P; Wojchowski, DM, 2009) |
| "Effects of fractions A and B from enzyme-digested traditional Chinese medicine colla corii asini on mice with 5-fluorouracil-induced anemia were investigated." | 3.74 | Hematopoietic effect of fractions from the enzyme-digested colla corii asini on mice with 5-fluorouracil induced anemia. ( Cui, S; Liu, J; Qin, Y; Wu, H; Yang, F; Zhang, Y, 2007) |
| "African-American patients with colorectal cancer were observed to have increased 5-fluorouracil (5-FU)-associated toxicity (leukopenia and anemia) and decreased overall survival compared with Caucasian patients." | 3.73 | Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. ( Desmond, RA; Diasio, RB; Fourie, J; Mattison, LK; Modak, A; Saif, MW, 2006) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 3.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| " We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients." | 3.72 | FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004) |
| " As a model toxicant, we chose 5-fluorouracil (5-FU), since we previously observed that maternal administration at 20-40 mg/kg on gestational day (GD) 14 produced fetal anemia on GD 16-17, as evidenced by dose-dependent decreases in the cell counts, hematocrit, and hemoglobin content of fetal blood obtained by cardiac puncture." | 3.69 | Flow cytometric detection of abnormal fetal erythropoiesis: application to 5-fluorouracil-induced anemia. ( Elstein, KH; Rogers, JM; Shuey, DL; Zucker, RM, 1995) |
| "Paclitaxel was administered intravenously on day 1 at a dose of 120 mg/m(2), and oral S-1 was administered twice a day from days 1 to 7, followed by a 7-day drug-free interval." | 2.79 | Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. ( Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2014) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 2.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer." | 2.74 | [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | 2.74 | Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Premenopausal breast cancer patients who developed anemia during the CMF regimen had significantly worse LRFS." | 2.73 | Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. ( Bartsch, R; Denison, U; Dubsky, P; Fridrik, M; Gnant, M; Greil, R; Hausmaninger, H; Jakesz, R; Kwasny, W; Mlineritsch, B; Pötter, R; Samonigg, H; Schippinger, W; Seifert, M; Sevelda, P; Steger, G; Stierer, M; Stöger, H; Taucher, S, 2008) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 2.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| " Thus, the recommended dosing schedule is level 2." | 2.72 | A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | 2.71 | Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| " The same dosage of combine drugs were used in the two groups." | 2.70 | [Phase III clinical study of a new anticancer drug atofluding]. ( Feng, FY; Han, J; Li, L; Li, Q; Sui, GJ; Wang, PH; Zhang, Y; Zhang, YC; Zhang, ZH; Zhou, MZ; Zhu, YG, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | 2.69 | Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | 2.69 | Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | 2.68 | [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Renal cell carcinoma is a common neoplasm that is often refractory to treatment." | 2.68 | A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. ( Blumenstein, BA; Crawford, ED; Elias, L; Flanigan, RC; Goodwin, JW; Kish, J; Lowe, BA; Wade, JL, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 2.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed." | 1.51 | Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. ( Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A, 2019) |
| "5% objective response) but an important morbidity with 10% toxic deaths in our very symptomatic population with a very important tumor burden." | 1.51 | [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. ( Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N, 2019) |
| "Depression was directly affected by fatigue (β=." | 1.43 | [Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer]. ( Lee, JR; Oh, PJ, 2016) |
| "A total of 196 stage II and III colon cancer patients were retrospectively enrolled in prospectively collected data." | 1.42 | T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. ( An, MS; Bae, KB; Choi, CS; Hong, KH; Hwang, JW; Kang, MS; Kim, BM; Kim, JH; Kim, KH; Oh, MK; Yoo, JH, 2015) |
| "The prognosis of stage IVB cervical cancer is generally poor." | 1.38 | Outcomes and toxicities for the treatment of stage IVB cervical cancer. ( Hwang, JH; Kang, S; Kim, JY; Lim, MC; Park, SY; Seo, SS, 2012) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| "Advanced pancreatic cancer has a poor prognosis." | 1.34 | [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. ( Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD, 2007) |
| "Treatment of non operable esophageal cancer still remains debatable." | 1.33 | [Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center]. ( François, E; Lagrange, JL; Magné, N; Marcy, PY; Touati, L; Van Houtte, P, 2005) |
| "In patients with locally advanced head and neck cancer a high initial rate of anemia was registered (41%): This rate was nearly doubled during chemoradiation (76%)." | 1.30 | [Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors]. ( Carl, UM; Hartmann, KA; Lammering, G; Pape, H, 1999) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (6.99) | 18.7374 |
| 1990's | 26 (18.18) | 18.2507 |
| 2000's | 49 (34.27) | 29.6817 |
| 2010's | 49 (34.27) | 24.3611 |
| 2020's | 9 (6.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ellis, H | 1 |
| De Francia, S | 1 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 1 |
| Mussa, MV | 1 |
| Kim, G | 1 |
| Cockrum, P | 1 |
| Surinach, A | 1 |
| Wang, S | 1 |
| Wainberg, Z | 1 |
| Myers, G | 1 |
| Wang, Y | 1 |
| Wang, Q | 1 |
| Friedman, A | 1 |
| Sanchez-Martinez, A | 1 |
| Liu, X | 1 |
| Singh, SA | 1 |
| Lim, KC | 1 |
| Khoriaty, R | 1 |
| Engel, JD | 1 |
| Yu, L | 1 |
| Panchenko, AV | 1 |
| Tyndyk, ML | 1 |
| Maydin, MA | 1 |
| Baldueva, IA | 1 |
| Artemyeva, AS | 1 |
| Kruglov, SS | 1 |
| Kireeva, GS | 1 |
| Golubev, AG | 1 |
| Belyaev, AM | 1 |
| Anisimov, VN | 1 |
| Wagner, AD | 1 |
| Grothey, A | 1 |
| Andre, T | 1 |
| Dixon, JG | 1 |
| Wolmark, N | 1 |
| Haller, DG | 1 |
| Allegra, CJ | 1 |
| de Gramont, A | 1 |
| VanCutsem, E | 1 |
| Alberts, SR | 1 |
| George, TJ | 1 |
| O'Connell, MJ | 2 |
| Twelves, C | 1 |
| Taieb, J | 1 |
| Saltz, LB | 1 |
| Blanke, CD | 1 |
| Francini, E | 1 |
| Kerr, R | 1 |
| Yothers, G | 1 |
| Seitz, JF | 1 |
| Marsoni, S | 1 |
| Goldberg, RM | 1 |
| Shi, Q | 1 |
| Deligonul, A | 1 |
| Aksoy, S | 2 |
| Tezcan, G | 1 |
| Tunca, B | 1 |
| Kanat, O | 1 |
| Cubukcu, E | 1 |
| Yilmazlar, T | 1 |
| Ozturk, E | 1 |
| Egeli, U | 1 |
| Cecener, G | 1 |
| Alemdar, A | 1 |
| Evrensel, T | 1 |
| Mie, T | 1 |
| Sasaki, T | 2 |
| Takeda, T | 1 |
| Fukuda, K | 1 |
| Furukawa, T | 1 |
| Yamada, Y | 1 |
| Kasuga, A | 1 |
| Matsuyama, M | 1 |
| Ozaka, M | 1 |
| Sasahira, N | 1 |
| Tian, Y | 1 |
| Xiang, Y | 1 |
| Wan, G | 1 |
| Wan, D | 1 |
| Zhu, H | 1 |
| Wang, T | 1 |
| Yang, X | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Reyngold, M | 1 |
| Shi, W | 1 |
| Zhang, Z | 2 |
| Cuaron, JJ | 1 |
| Crane, CH | 1 |
| O'Reilly, EM | 1 |
| Lowery, MA | 1 |
| Yu, KH | 1 |
| Goodman, KA | 2 |
| Wu, AJ | 2 |
| de Castro Junior, G | 1 |
| Segalla, JG | 1 |
| de Azevedo, SJ | 1 |
| Andrade, CJ | 1 |
| Grabarz, D | 1 |
| de Araújo Lima França, B | 1 |
| Del Giglio, A | 1 |
| Lazaretti, NS | 1 |
| Álvares, MN | 1 |
| Pedrini, JL | 1 |
| Kussumoto, C | 1 |
| de Matos Neto, JN | 1 |
| Forones, NM | 1 |
| Fernandes Júnior, HJ | 1 |
| Borges, G | 1 |
| Girotto, G | 1 |
| da Silva, IDCG | 1 |
| Maluf-Filho, F | 1 |
| Skare, NG | 1 |
| Masuishi, T | 1 |
| Kadowaki, S | 1 |
| Kondo, M | 1 |
| Komori, A | 1 |
| Sugiyama, K | 1 |
| Mitani, S | 1 |
| Honda, K | 1 |
| Narita, Y | 1 |
| Taniguchi, H | 1 |
| Ura, T | 3 |
| Ando, M | 1 |
| Mishima, H | 1 |
| Muro, K | 1 |
| Abdel-Rahman, O | 1 |
| Bernadach, M | 1 |
| Lapeyre, M | 1 |
| Dillies, AF | 1 |
| Miroir, J | 1 |
| Moreau, J | 1 |
| Kwiatkowski, F | 1 |
| Pham-Dang, N | 1 |
| Saroul, N | 1 |
| Durando, X | 1 |
| Biau, J | 1 |
| Papneja, N | 1 |
| Zaidi, A | 1 |
| Chalchal, H | 1 |
| Moser, M | 1 |
| Tan, K | 1 |
| Olson, C | 1 |
| Haider, K | 1 |
| Shaw, J | 1 |
| Ahmed, S | 1 |
| Yasuda, T | 1 |
| Tanaka, O | 1 |
| Hayashi, S | 1 |
| Nakahata, Y | 1 |
| Yasuda, Y | 1 |
| Omatsu, T | 1 |
| Obora, A | 1 |
| Kojima, T | 2 |
| Matsuo, M | 1 |
| Yagi, N | 1 |
| Tanriverdi, O | 1 |
| Saridaki, Z | 1 |
| Lambrodimou, G | 1 |
| Kachris, S | 1 |
| Makrantonakis, P | 1 |
| Boukovinas, I | 1 |
| Polyzos, A | 2 |
| Anagnostopoulos, A | 1 |
| Athanasiadis, A | 2 |
| Stoltidis, D | 1 |
| Georgoulias, V | 2 |
| Souglakos, J | 1 |
| Rubovszky, G | 1 |
| Láng, I | 1 |
| Ganofszky, E | 1 |
| Horváth, Z | 1 |
| Juhos, E | 1 |
| Nagy, T | 1 |
| Szabó, E | 1 |
| Szentirmay, Z | 1 |
| Budai, B | 1 |
| Hitre, E | 1 |
| Oh, MJ | 1 |
| Lee, HJ | 1 |
| Lee, SH | 2 |
| Hironaka, S | 1 |
| Ueda, S | 1 |
| Yasui, H | 1 |
| Nishina, T | 1 |
| Tsuda, M | 1 |
| Tsumura, T | 1 |
| Sugimoto, N | 1 |
| Shimodaira, H | 1 |
| Tokunaga, S | 1 |
| Moriwaki, T | 1 |
| Esaki, T | 1 |
| Nagase, M | 1 |
| Fujitani, K | 1 |
| Yamaguchi, K | 1 |
| Hamamoto, Y | 1 |
| Morita, S | 1 |
| Okamoto, I | 1 |
| Boku, N | 1 |
| Hyodo, I | 1 |
| Liu, Y | 1 |
| Wu, W | 1 |
| Hong, W | 1 |
| Sun, X | 1 |
| Wu, J | 1 |
| Huang, Q | 1 |
| Meyer, T | 1 |
| Qian, W | 1 |
| Caplin, ME | 1 |
| Armstrong, G | 1 |
| Lao-Sirieix, SH | 1 |
| Hardy, R | 1 |
| Valle, JW | 1 |
| Talbot, DC | 1 |
| Cunningham, D | 2 |
| Reed, N | 1 |
| Shaw, A | 1 |
| Navalkissoor, S | 1 |
| Luong, TV | 1 |
| Corrie, PG | 1 |
| Mahoney, SE | 2 |
| Davis, JM | 2 |
| Murphy, EA | 2 |
| McClellan, JL | 2 |
| Pena, MM | 2 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Higuchi, K | 1 |
| Komori, S | 1 |
| Tanabe, S | 1 |
| Katada, C | 1 |
| Azuma, M | 1 |
| Ishiyama, H | 1 |
| Ishido, K | 1 |
| Katada, N | 1 |
| Hayakawa, K | 1 |
| Koizumi, W | 1 |
| Yanagihara, Y | 1 |
| Tanji, N | 1 |
| Miura, N | 1 |
| Shirato, A | 1 |
| Nishimura, K | 1 |
| Fukumoto, T | 1 |
| Azuma, K | 1 |
| Miyauchi, Y | 1 |
| Kikugawa, T | 1 |
| Yokoyama, M | 1 |
| Zheng, Y | 2 |
| Fang, W | 1 |
| Mao, C | 1 |
| Qian, J | 1 |
| Zhao, P | 1 |
| Zhang, X | 1 |
| Jiang, H | 1 |
| Xu, N | 1 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| An, MS | 1 |
| Yoo, JH | 1 |
| Kim, KH | 1 |
| Bae, KB | 1 |
| Choi, CS | 1 |
| Hwang, JW | 1 |
| Kim, JH | 2 |
| Kim, BM | 1 |
| Kang, MS | 1 |
| Oh, MK | 1 |
| Hong, KH | 1 |
| Julie, DA | 1 |
| Oh, JH | 1 |
| Apte, AP | 1 |
| Deasy, JO | 1 |
| Tom, A | 1 |
| Badiyan, SN | 1 |
| Olsen, JR | 1 |
| Lee, AY | 1 |
| Yano, M | 1 |
| Menias, CO | 1 |
| Khwaja, S | 1 |
| Wang-Gillam, A | 1 |
| Strasberg, SM | 1 |
| Hawkins, WG | 1 |
| Linehan, DC | 1 |
| Myerson, RJ | 1 |
| Parikh, PJ | 1 |
| Kwon, HJ | 1 |
| Park, MI | 1 |
| Park, SJ | 1 |
| Moon, W | 1 |
| Kim, SE | 1 |
| Lee, HW | 2 |
| Choi, YJ | 1 |
| Ogata, Y | 2 |
| Shimokawa, M | 1 |
| Tanaka, T | 3 |
| Emi, Y | 1 |
| Oki, E | 1 |
| Saeki, H | 1 |
| Sadanaga, N | 1 |
| Kusumoto, T | 1 |
| Touyama, T | 1 |
| Kimura, M | 1 |
| Baba, H | 1 |
| Akagi, Y | 1 |
| Shirouzu, K | 1 |
| Maehara, Y | 1 |
| Shahriari-Ahmadi, A | 1 |
| Fahimi, A | 1 |
| Payandeh, M | 1 |
| Sadeghi, M | 1 |
| Wu, H | 2 |
| Ren, C | 1 |
| Yang, F | 2 |
| Qin, Y | 2 |
| Zhang, Y | 3 |
| Liu, J | 2 |
| Zhao, L | 1 |
| Liu, R | 1 |
| Li, T | 1 |
| Li, F | 1 |
| Liu, H | 1 |
| Li, G | 2 |
| Oh, PJ | 1 |
| Lee, JR | 1 |
| Takata, T | 1 |
| Yahagi, N | 1 |
| Yahagi, R | 1 |
| Tsuchida, H | 1 |
| Ishigaki, Y | 1 |
| Tomosugi, N | 1 |
| Fushiya, S | 2 |
| Takano, F | 2 |
| Ohta, T | 1 |
| Vermorken, JB | 1 |
| Mesia, R | 1 |
| Rivera, F | 1 |
| Remenar, E | 1 |
| Kawecki, A | 1 |
| Rottey, S | 1 |
| Erfan, J | 1 |
| Zabolotnyy, D | 1 |
| Kienzer, HR | 1 |
| Cupissol, D | 1 |
| Peyrade, F | 1 |
| Benasso, M | 1 |
| Vynnychenko, I | 1 |
| De Raucourt, D | 1 |
| Bokemeyer, C | 1 |
| Schueler, A | 1 |
| Amellal, N | 1 |
| Hitt, R | 1 |
| Bogacheva, O | 1 |
| Bogachev, O | 1 |
| Menon, M | 1 |
| Dev, A | 1 |
| Houde, E | 1 |
| Valoret, EI | 1 |
| Prosser, HM | 1 |
| Creasy, CL | 1 |
| Pickering, SJ | 1 |
| Grau, E | 1 |
| Rance, K | 1 |
| Livi, GP | 1 |
| Karur, V | 2 |
| Erickson-Miller, CL | 1 |
| Wojchowski, DM | 2 |
| Agosti, V | 1 |
| Sathyanarayana, P | 1 |
| Besmer, P | 1 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| AL-Ashry, MS | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Orphanos, G | 1 |
| Alexopoulos, A | 1 |
| Malliou, S | 1 |
| Ioannidis, G | 1 |
| Ardavanis, A | 1 |
| Kandylis, C | 1 |
| Stavrakakis, J | 1 |
| Rigatos, G | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Szczylik, C | 1 |
| Lu, M | 1 |
| Shen, L | 2 |
| Li, J | 2 |
| Li, Y | 1 |
| Zhang, XD | 2 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 2 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 1 |
| Hochhaus, A | 3 |
| Hofheinz, RD | 3 |
| Kong, L | 1 |
| Zhang, YW | 1 |
| Hu, CS | 1 |
| Guo, Y | 1 |
| Gao, J | 1 |
| Hu, JY | 1 |
| Xia, YF | 1 |
| Yi, W | 1 |
| Tao, YL | 1 |
| Yürek, S | 1 |
| Riess, H | 1 |
| Kreher, S | 1 |
| Dörken, B | 1 |
| Salama, A | 1 |
| Savva-Bordalo, J | 1 |
| Ramalho-Carvalho, J | 1 |
| Pinheiro, M | 1 |
| Costa, VL | 1 |
| Rodrigues, A | 1 |
| Dias, PC | 1 |
| Veiga, I | 1 |
| Machado, M | 1 |
| Teixeira, MR | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Untch, M | 1 |
| von Minckwitz, G | 1 |
| Konecny, GE | 1 |
| Conrad, U | 1 |
| Fett, W | 1 |
| Kurzeder, C | 1 |
| Lück, HJ | 1 |
| Stickeler, E | 1 |
| Urbaczyk, H | 1 |
| Liedtke, B | 1 |
| Beckmann, MW | 1 |
| Salat, C | 1 |
| Harbeck, N | 1 |
| Müller, V | 1 |
| Schmidt, M | 1 |
| Hasmüller, S | 1 |
| Lenhard, M | 1 |
| Nekljudova, V | 1 |
| Lebeau, A | 1 |
| Loibl, S | 1 |
| Fasching, PA | 1 |
| Hara, T | 1 |
| Nishikawa, K | 1 |
| Sakatoku, M | 1 |
| Oba, K | 1 |
| Sakamoto, J | 2 |
| Omura, K | 1 |
| Ikeda, E | 1 |
| Kaneko, K | 1 |
| Minashi, K | 1 |
| Onozawa, M | 1 |
| Nihei, K | 1 |
| Fuse, N | 1 |
| Yano, T | 1 |
| Yoshino, T | 1 |
| Tahara, M | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Dakik, HK | 1 |
| Moskovic, DJ | 1 |
| Carlson, PJ | 1 |
| Tamm, EP | 1 |
| Qiao, W | 1 |
| Wolff, RA | 1 |
| Abbruzzese, JL | 1 |
| Fogelman, DR | 1 |
| Hwang, JH | 1 |
| Lim, MC | 1 |
| Seo, SS | 1 |
| Kang, S | 1 |
| Park, SY | 1 |
| Kim, JY | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Farid, M | 1 |
| Chowbay, B | 1 |
| Chen, X | 1 |
| Tan, SH | 1 |
| Ramasamy, S | 1 |
| Koo, WH | 1 |
| Toh, HC | 1 |
| Choo, SP | 1 |
| Ong, SY | 1 |
| Zarogoulidis, P | 1 |
| Chatzaki, E | 1 |
| Hohenforst-Schmidt, W | 1 |
| Goldberg, EP | 1 |
| Galaktidou, G | 1 |
| Kontakiotis, T | 1 |
| Karamanos, N | 1 |
| Zarogoulidis, K | 1 |
| Lim, KH | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 2 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 1 |
| Gordon, B | 1 |
| Uncu, D | 1 |
| Çetin, B | 1 |
| Yetişyiğit, T | 1 |
| Özdemir, N | 1 |
| Berk, V | 1 |
| Dane, F | 1 |
| Inal, A | 1 |
| Harputluoğlu, H | 1 |
| Budakoğlu, B | 1 |
| Koca, D | 1 |
| Sevinç, A | 1 |
| Cihan, S | 1 |
| Durnalı, AG | 1 |
| Özkan, M | 1 |
| Öztürk, MA | 1 |
| Işıkdoğan, A | 1 |
| Büyükberber, S | 1 |
| Benekli, M | 1 |
| Köş, T | 1 |
| Alkış, N | 1 |
| Karaca, H | 1 |
| Turhal, NS | 1 |
| Zengin, N | 1 |
| Li, Q | 1 |
| Feng, FY | 1 |
| Han, J | 1 |
| Sui, GJ | 1 |
| Zhu, YG | 1 |
| Zhang, ZH | 1 |
| Li, L | 1 |
| Wang, PH | 1 |
| Zhou, MZ | 1 |
| Zhang, YC | 1 |
| van Kuilenburg, AB | 1 |
| Baars, JW | 1 |
| Meinsma, R | 1 |
| van Gennip, AH | 1 |
| Shirao, K | 1 |
| Stathopoulos, GP | 1 |
| Syrigos, K | 1 |
| Fountzilas, G | 1 |
| Rigatos, SK | 1 |
| Ziras, N | 1 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Androulakis, N | 1 |
| Aravantinos, G | 1 |
| Papakotoulas, P | 1 |
| Ghi, MG | 1 |
| Paccagnella, A | 1 |
| D'Amanzo, P | 1 |
| Mione, CA | 1 |
| Fasan, S | 1 |
| Paro, S | 1 |
| Mastromauro, C | 1 |
| Carnuccio, R | 1 |
| Turcato, G | 1 |
| Gatti, C | 1 |
| Pallini, A | 1 |
| Nascimben, O | 1 |
| Biason, R | 1 |
| Oniga, F | 1 |
| Medici, M | 1 |
| Rossi, F | 1 |
| Fila, G | 1 |
| Voelter, V | 2 |
| Schuhmacher, C | 2 |
| Busch, R | 2 |
| Peschel, C | 2 |
| Siewert, JR | 2 |
| Lordick, F | 2 |
| Hatano, R | 1 |
| Michimata, M | 1 |
| Kazama, I | 1 |
| Suzuki, M | 1 |
| Matsubara, M | 1 |
| Mouret-Reynier, MA | 1 |
| Abrial, CJ | 1 |
| Ferrière, JP | 2 |
| Amat, S | 1 |
| Curé, HD | 1 |
| Kwiatkowski, FG | 1 |
| Feillel, VA | 1 |
| Lebouëdec, G | 1 |
| Penault-Llorca, FM | 1 |
| Chollet, PJ | 1 |
| Raab, B | 1 |
| Mai, S | 1 |
| Wenz, F | 1 |
| Willeke, F | 1 |
| Emig, M | 1 |
| Buchheidt, D | 1 |
| Hehlmann, R | 1 |
| Di Lorenzo, G | 1 |
| Autorino, R | 1 |
| Giordano, A | 1 |
| Giuliano, M | 1 |
| D'Armiento, M | 1 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Magné, N | 1 |
| François, E | 1 |
| Touati, L | 1 |
| Marcy, PY | 1 |
| Van Houtte, P | 1 |
| Lagrange, JL | 1 |
| Prosnitz, RG | 1 |
| Yao, B | 1 |
| Farrell, CL | 1 |
| Clough, R | 1 |
| Brizel, DM | 1 |
| Kondo, K | 1 |
| Kobayashi, M | 1 |
| Kojima, H | 1 |
| Hirabayashi, N | 1 |
| Kataoka, M | 1 |
| Araki, K | 1 |
| Matsui, T | 1 |
| Takiyama, W | 1 |
| Miyashita, Y | 1 |
| Nakazato, H | 1 |
| Nakao, A | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Skopelitis, H | 1 |
| Gouveris, P | 1 |
| Kopterides, P | 1 |
| Kopteridis, P | 1 |
| Loukeris, D | 1 |
| Sigala, F | 1 |
| Zorbala-Sypsa, A | 1 |
| Felekouras, E | 1 |
| Papalambros, E | 1 |
| Park, SH | 2 |
| Lee, J | 1 |
| Park, JO | 1 |
| Kim, K | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Park, YS | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Kim, S | 1 |
| Bang, SM | 3 |
| Cho, EK | 2 |
| Shin, DB | 2 |
| Lee, JH | 2 |
| Jansen, C | 1 |
| Miaskowski, C | 1 |
| Dodd, M | 1 |
| Dowling, G | 1 |
| Kramer, J | 1 |
| Sato, Y | 1 |
| Takayama, T | 1 |
| Sagawa, T | 1 |
| Okamoto, T | 1 |
| Miyanishi, K | 1 |
| Sato, T | 1 |
| Araki, H | 1 |
| Iyama, S | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Takimoto, R | 1 |
| Nagakura, H | 1 |
| Hareyama, M | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Weissenberger, C | 1 |
| Geissler, M | 1 |
| Otto, F | 1 |
| Barke, A | 1 |
| Henne, K | 1 |
| von Plehn, G | 1 |
| Rein, A | 1 |
| Muller, C | 1 |
| Bartelt, S | 1 |
| Henke, M | 1 |
| Ferrandina, G | 1 |
| Distefano, M | 1 |
| Smaniotto, D | 1 |
| Morganti, A | 1 |
| Paglia, A | 1 |
| Macchia, G | 1 |
| Corvari, B | 1 |
| Lorusso, D | 1 |
| Scambia, G | 1 |
| Tampellini, M | 1 |
| Saini, A | 1 |
| Alabiso, I | 1 |
| Bitossi, R | 1 |
| Brizzi, MP | 1 |
| Sculli, CM | 1 |
| Berruti, A | 1 |
| Gorzegno, G | 1 |
| Magnino, A | 1 |
| Sperti, E | 1 |
| Miraglia, S | 1 |
| Forti, L | 1 |
| Alabiso, O | 1 |
| Aglietta, M | 1 |
| Harris, A | 1 |
| Dogliotti, L | 1 |
| Abbrederis, K | 1 |
| Bassermann, F | 1 |
| Roethling, N | 1 |
| Sendler, A | 1 |
| Fagnoni, P | 1 |
| Limat, S | 1 |
| Chaigneau, L | 1 |
| Guardiola, E | 1 |
| Briaud, S | 1 |
| Schmitt, B | 1 |
| Merrouche, Y | 1 |
| Pivot, X | 1 |
| Woronoff-Lemsi, MC | 1 |
| Demizu, Y | 1 |
| Sasaki, R | 1 |
| Soejima, T | 1 |
| Maruta, T | 1 |
| Okamoto, Y | 1 |
| Yamada, K | 1 |
| Yoden, E | 1 |
| Ejima, Y | 1 |
| Ota, Y | 1 |
| Ishida, H | 1 |
| Nibu, K | 1 |
| Sugimura, K | 1 |
| Mattison, LK | 1 |
| Fourie, J | 1 |
| Desmond, RA | 1 |
| Modak, A | 1 |
| Saif, MW | 1 |
| Diasio, RB | 1 |
| Gaffney, DK | 1 |
| Winter, K | 1 |
| Dicker, AP | 1 |
| Miller, B | 1 |
| Eifel, PJ | 1 |
| Ryu, J | 1 |
| Avizonis, V | 1 |
| Fromm, M | 1 |
| Greven, K | 1 |
| Liu, K | 1 |
| Wang, GB | 1 |
| Cheng, B | 1 |
| Qiu, DB | 1 |
| Park, JY | 1 |
| Ahn, SH | 1 |
| Yoon, YJ | 1 |
| Kim, JK | 1 |
| Lee, DY | 1 |
| Chon, CY | 1 |
| Moon, YM | 1 |
| Han, KH | 1 |
| Schneider, BJ | 1 |
| El-Rayes, B | 1 |
| Muler, JH | 1 |
| Philip, PA | 1 |
| Kalemkerian, GP | 1 |
| Griffith, KA | 1 |
| Zalupski, MM | 1 |
| Gianni, L | 1 |
| Cole, BF | 1 |
| Panzini, I | 1 |
| Snyder, R | 1 |
| Holmberg, SB | 1 |
| Byrne, M | 1 |
| Crivellari, D | 1 |
| Colleoni, M | 1 |
| Aebi, S | 1 |
| Simoncini, E | 1 |
| Pagani, O | 1 |
| Castiglione-Gertsch, M | 1 |
| Price, KN | 1 |
| Goldhirsch, A | 1 |
| Coates, AS | 1 |
| Ravaioli, A | 1 |
| Nam, E | 1 |
| Xie, FY | 1 |
| Qi, SN | 1 |
| Hu, WH | 1 |
| Zou, GR | 1 |
| Peng, M | 1 |
| Li, JS | 1 |
| Gong, JF | 1 |
| Di, LJ | 1 |
| Jin, ML | 1 |
| Cui, S | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Lee, S | 1 |
| Lee, DM | 1 |
| Yoo, HS | 1 |
| Kim, SH | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Jeong, JS | 1 |
| Kim, HJ | 1 |
| Dubsky, P | 1 |
| Sevelda, P | 1 |
| Jakesz, R | 1 |
| Hausmaninger, H | 1 |
| Samonigg, H | 1 |
| Seifert, M | 1 |
| Denison, U | 1 |
| Mlineritsch, B | 1 |
| Steger, G | 1 |
| Kwasny, W | 1 |
| Stöger, H | 1 |
| Bartsch, R | 1 |
| Stierer, M | 1 |
| Taucher, S | 1 |
| Fridrik, M | 1 |
| Schippinger, W | 1 |
| Greil, R | 1 |
| Pötter, R | 1 |
| Gnant, M | 1 |
| Aispuru, GR | 1 |
| Aguirre, MV | 1 |
| Aquino-Esperanza, JA | 1 |
| Lettieri, CN | 1 |
| Juaristi, JA | 1 |
| Brandan, NC | 1 |
| Bruckner, HW | 1 |
| Cohen, J | 1 |
| Shamberger, RC | 1 |
| Devereux, DF | 1 |
| Brennan, MF | 1 |
| Moertel, CG | 1 |
| Frytak, S | 1 |
| Hahn, RG | 1 |
| Reitemeier, RJ | 1 |
| Rubin, J | 1 |
| Schutt, AJ | 1 |
| Weiland, LH | 1 |
| Childs, DS | 1 |
| Holbrook, MA | 1 |
| Lavin, PT | 1 |
| Livstone, E | 1 |
| Spiro, H | 1 |
| Knowlton, A | 1 |
| Kalser, M | 1 |
| Barkin, J | 1 |
| Lessner, H | 1 |
| Mann-Kaplan, R | 1 |
| Ramming, K | 1 |
| Douglas, HO | 1 |
| Thomas, P | 1 |
| Nave, H | 1 |
| Bateman, J | 1 |
| Lokich, J | 1 |
| Brooks, J | 1 |
| Chaffey, J | 1 |
| Corson, JM | 1 |
| Zamcheck, N | 1 |
| Novak, JW | 1 |
| Kalechman, Y | 1 |
| Rushkin, G | 1 |
| Nerubay, J | 1 |
| Albeck, M | 1 |
| Sredni, B | 1 |
| Zucker, RM | 2 |
| Elstein, KH | 2 |
| Shuey, DL | 2 |
| Rogers, JM | 2 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Ohta, M | 1 |
| Yamaguchi, Y | 1 |
| Fujii, M | 1 |
| Asakawa, M | 1 |
| Fukuoka, M | 1 |
| Yoshida, K | 1 |
| Niitani, H | 1 |
| Gasparini, G | 1 |
| Caffo, O | 1 |
| Barni, S | 1 |
| Frontini, L | 1 |
| Testolin, A | 1 |
| Guglielmi, RB | 1 |
| Ambrosini, G | 1 |
| Ardizzoni, A | 1 |
| Venturini, M | 2 |
| Sertoli, MR | 2 |
| Giannessi, PG | 1 |
| Brema, F | 1 |
| Danova, M | 1 |
| Testore, F | 1 |
| Mariani, GL | 1 |
| Pennucci, MC | 1 |
| Queirolo, P | 1 |
| Williamson, SK | 1 |
| Tangen, CM | 1 |
| Maddox, AM | 1 |
| Spiridonidis, CH | 1 |
| Macdonald, JS | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| García-Girón, C | 1 |
| Espinosa, E | 1 |
| García-Alfonso, P | 1 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 1 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Elias, L | 1 |
| Blumenstein, BA | 1 |
| Kish, J | 1 |
| Flanigan, RC | 1 |
| Wade, JL | 1 |
| Lowe, BA | 1 |
| Goodwin, JW | 1 |
| Crawford, ED | 1 |
| Fujinami, K | 1 |
| Ikeda, I | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| Del Mastro, L | 1 |
| Costantini, M | 1 |
| Garrone, O | 1 |
| Bertelli, G | 1 |
| Machì, AM | 1 |
| Rosso, R | 1 |
| Aranda, E | 1 |
| Cervantes, A | 1 |
| Carrato, A | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Fernández-Martos, C | 1 |
| Díaz-Rubio, E | 2 |
| Chollet, P | 1 |
| Charrier, S | 1 |
| Brain, E | 1 |
| Curé, H | 1 |
| van Praagh, I | 1 |
| Feillel, V | 1 |
| de Latour, M | 1 |
| Dauplat, J | 1 |
| Misset, JL | 1 |
| Klaassen, U | 1 |
| Seeber, S | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Yen, CC | 2 |
| Tung, SL | 2 |
| Hsieh, RK | 2 |
| Chiou, TJ | 2 |
| Liu, JH | 2 |
| Wang, WS | 2 |
| Chen, PM | 2 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 1 |
| Monaco, F | 1 |
| Einhorn, LH | 1 |
| Tsukuda, M | 1 |
| Yuyama, S | 1 |
| Kohno, H | 1 |
| Itoh, K | 1 |
| Kokatsu, T | 1 |
| Kawai, S | 1 |
| Kikuyama, S | 1 |
| Inada, T | 1 |
| Miyakita, M | 1 |
| Fan, FS | 1 |
| Lammering, G | 1 |
| Carl, UM | 1 |
| Pape, H | 1 |
| Hartmann, KA | 1 |
| Kohno, N | 1 |
| Kitahara, S | 1 |
| Tamura, E | 1 |
| Tanabe, T | 1 |
| Nakanoboh, M | 1 |
| Kawada, M | 1 |
| Shirasaka, T | 1 |
| Heo, DS | 1 |
| Lee, KH | 1 |
| Byun, JH | 1 |
| Chang, HM | 1 |
| Noh, DY | 1 |
| Choe, KJ | 1 |
| Kim, SR | 1 |
| Kim, NK | 1 |
| Chau, I | 1 |
| Webb, A | 1 |
| Hill, M | 1 |
| Waters, JS | 1 |
| Norman, A | 1 |
| Massey, A | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| van Laar, JA | 1 |
| van der Wilt, CL | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Peters, GJ | 1 |
| Flaherty, L | 1 |
| Wozniak, A | 1 |
| Redman, B | 1 |
| Kraut, M | 1 |
| Martino, S | 1 |
| Heilbrun, L | 1 |
| Valdivieso, M | 1 |
| Arnold, J | 1 |
| Ellis, S | 1 |
| Radley, JM | 1 |
| Williams, N | 1 |
| Matsumoto, T | 1 |
| Endoh, K | 1 |
| Kamisango, K | 1 |
| Akamatsu, K | 1 |
| Koizumi, K | 1 |
| Higuchi, M | 1 |
| Imai, N | 1 |
| Mitsui, H | 1 |
| Kawaguchi, T | 1 |
| Recondo, G | 1 |
| Benhamed, M | 1 |
| Cvitkovic, E | 1 |
| Marandas, P | 1 |
| Armand, JP | 1 |
| Nakano, T | 2 |
| Waki, N | 2 |
| Asai, H | 2 |
| Kitamura, Y | 2 |
| Kastl, J | 1 |
| Horácek, J | 1 |
| Fleischhacker, H | 1 |
| Di Pietro, S | 1 |
| De Palo, GM | 1 |
| Gennari, L | 1 |
| Molinari, R | 1 |
| Damascelli, B | 1 |
| Chernyĭ, VA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer[NCT01249352] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by P[NCT00544232] | Phase 3 | 720 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Clinical Trial of the Neoadjuvant Standard Chemotherapy 3 FEC 100 + 3 TAXOTERE Protocol Versus the Same Protocol Adapted as a Function of Clinical Response[NCT00425516] | Phase 2 | 264 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
7 reviews available for fluorouracil and Anemia
| Article | Year |
|---|---|
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Topics: Adenoviridae; Aged; Anemia; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Carcinoma, N | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cycloph | 2005 |
The effect of chemotherapeutic agents on wound healing.
Topics: Adrenal Cortex Hormones; Anemia; Animals; Antineoplastic Agents; Azathioprine; Collagen; Cyclophosph | 1981 |
62 trials available for fluorouracil and Anemia
| Article | Year |
|---|---|
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2018 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothera | 2013 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian Peo | 2014 |
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Area Under Curve; Carcinoma, | 2016 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be | 2016 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2010 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy | 2010 |
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 2011 |
Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin | 2011 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C | 2012 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
[Phase III clinical study of a new anticancer drug atofluding].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Female; Fluorouracil; Humans; Leukopenia; Male; Middle A | 2002 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubic | 2004 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relatio | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2005 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Datab | 2006 |
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamid | 2007 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
Topics: Adult; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast | 2008 |
A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Blood Cell Count; Endpoint Determination; Eryt | 2008 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuv | 2008 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1994 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1994 |
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1996 |
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 1996 |
Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor.
Topics: Anemia; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylat | 1997 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Drug Adm | 1998 |
Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubici | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admini | 1998 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuv | 2000 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 1991 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
74 other studies available for fluorouracil and Anemia
| Article | Year |
|---|---|
Management of fluorouracil toxicity in a Labrador retriever-poodle crossbred dog.
Topics: Anemia; Animals; Dog Diseases; Dogs; Fluorouracil; Male; Thrombocytopenia | 2022 |
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Murine erythroid differentiation kinetics in vivo under normal and anemic stress conditions.
Topics: Anemia; Animals; Bone Marrow; Cell Differentiation; Fluorouracil; Hematopoietic Stem Cells; Mice | 2023 |
Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.
Topics: Anemia; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diseas | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bi | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De | 2021 |
Effects and mechanisms of Bazhen decoction, Siwu decoction, and\
Sijunzi decoction on 5-fluorouracil-induced anemia in mice.
Topics: Anemia; Animals; Bone Marrow Cells; Cell Cycle; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; | 2016 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2017 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community He | 2019 |
Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
Topics: Abdominal Pain; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothe | 2020 |
Predictive value of baseline plasma D-dimers for chemotherapy- induced thrombocytopenia in patients with stage III colon cancer: a pilot study.
Topics: Adult; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curv | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2015 |
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease- | 2013 |
Dietary quercetin reduces chemotherapy-induced fatigue in mice.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dietary Supplements; Disease Model | 2014 |
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2013 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carci | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progressi | 2015 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cape | 2015 |
Extraction and identification of collagen-derived peptides with hematopoietic activity from Colla Corii Asini.
Topics: Anemia; Animals; Blood Cell Count; Collagen; Drugs, Chinese Herbal; Erythroid Precursor Cells; Femal | 2016 |
[Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Anxiety; Camptothecin; Cognitive Dysfunction; Depression | 2016 |
The liquid culture filtrates of entomogenous fungus Paecilomyces tenuipes and its glycoprotein constituent protects against anemia in mice treated with 5-fluorouracil.
Topics: Anemia; Animals; Antimetabolites; Blood Cell Count; Bone Marrow Cells; Chromatography, High Pressure | 2008 |
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Topics: Alleles; Anemia; Animals; Antigens, CD; Bone Marrow Transplantation; Cell Line; Erythropoiesis; Fluo | 2008 |
A KIT juxtamembrane PY567 -directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis.
Topics: Amino Acid Substitution; Anemia; Animals; Antimetabolites, Antineoplastic; Erythroid Precursor Cells | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplast | 2010 |
Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2010 |
Fatal immune haemolysis due to antibodies to individual metabolites of 5-fluorouracil.
Topics: Anemia; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2010 |
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Do | 2012 |
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Com | 2012 |
Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dose-Response Relationship, Drug; | 2013 |
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dise | 2004 |
Water-soluble extracts from Angelica acutiloba Kitagawa enhance hematopoiesis by activating immature erythroid cells in mice with 5-fluorouracil-induced anemia.
Topics: Anemia; Angelica; Animals; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Eryt | 2004 |
Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2004 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
[Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Disease-Free Survival; Female; Fluorouracil; Hemoglobins; Human | 2006 |
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviva | 2006 |
Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; C | 2006 |
Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2006 |
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Topics: Adult; Aged; Anemia; Black or African American; Breath Tests; Carbon Dioxide; Colorectal Neoplasms; | 2006 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2007 |
Hematopoietic effect of fractions from the enzyme-digested colla corii asini on mice with 5-fluorouracil induced anemia.
Topics: Anemia; Animals; Base Sequence; Bone Marrow; DNA Primers; Enzymes; Erythropoietin; Female; Fluoroura | 2007 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Erythroid expansion and survival in response to acute anemia stress: the role of EPO receptor, GATA-1, Bcl-xL and caspase-3.
Topics: Acute Disease; Anemia; Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Bone Marrow Ce | 2008 |
MTX/5-FU trials in gastrointestinal and other cancers.
Topics: Aged; Anemia; Conjunctivitis; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Gastrointest | 1983 |
Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
Topics: Adjuvants, Immunologic; Anemia; Animals; Antineoplastic Agents; Bone Marrow Diseases; Cells, Culture | 1995 |
Flow cytometric detection of abnormal fetal erythropoiesis: application to 5-fluorouracil-induced anemia.
Topics: Anemia; Animals; Erythrocyte Count; Erythroid Precursor Cells; Erythropoiesis; Female; Fetal Blood; | 1995 |
Fetal anemia following maternal exposure to 5-fluorouracil in the rat.
Topics: Anemia; Animals; Embryonic and Fetal Development; Erythropoiesis; Female; Fetal Diseases; Fluorourac | 1994 |
Clinical and pathological response to primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1997 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
[Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors].
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |
Compensatory mechanisms in platelet production: the response of Sl/Sld mice to 5-fluorouracil.
Topics: Anemia; Animals; Blood Cell Count; Blood Platelets; Cell Division; Fluorouracil; Hematocrit; Male; M | 1991 |
Effect of recombinant human erythropoietin on anticancer drug-induced anaemia.
Topics: Anemia; Animals; Cisplatin; Erythropoietin; Fluorouracil; Hemoglobins; Male; Rats; Rats, Inbred Stra | 1990 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
Effect of 5-fluorouracil on "primitive" hematopoietic stem cells that reconstitute whole erythropoiesis of genetically anemic W/Wv mice.
Topics: Anemia; Animals; Bone Marrow Transplantation; Disease Models, Animal; Erythrocytes; Erythropoiesis; | 1989 |
Long-term monoclonal reconstitution of erythropoiesis in genetically anemic W/Wv mice by injection of 5-fluorouracil-treated bone marrow cells of Pgk-1b/Pgk-1a mice.
Topics: Anemia; Animals; Colony-Forming Units Assay; Erythropoiesis; Fluorouracil; Hematopoietic Stem Cell T | 1987 |
[Multiple basalomas following long-term intake of arsenic].
Topics: Administration, Oral; Administration, Topical; Anemia; Arsenic; Arsenites; Carcinoma, Basal Cell; Fe | 1985 |
[Therapy of anemias].
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anemia, Sideroblastic; Azathioprine; Dacti | 1970 |
Cancer chemotherapy by intra-arterial infusion with adriamycin.
Topics: Adult; Alopecia; Anemia; Doxorubicin; Electrocardiography; Female; Femoral Artery; Fluorouracil; Hea | 1973 |
[The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
Topics: Anemia; Fluorouracil; Humans; Leukopenia; Melphalan; Nitrogen Mustard Compounds; Stomach Neoplasms; | 1970 |